
Private companies that sell COVID-19 tests to holidaymakers have been told to “get on the right side of the law” by the competition regulator, after widespread allegations of poor service triggered a government crackdown.
Days after the health secretary, Sajid Javid, said “cowboy” PCR test firms could be removed from the government’s list of approved providers, the Competition and Markets Authority (CMA) issued a separate warning.
Related: UK Lowers Cost Of COVID-19 Travel Tests After Probe
It stated rogue companies could face enforcement action from the CMA itself or from National Trading Standards if they are found to be breaking consumer law by misleading customers or treating them unfairly.
It follows multiple allegations that private providers, who are thought to have made £500 million since the return of international leisure travel in mid-May, failed to deliver tests, send results, and process refunds.
In an open letter to PCR test firms, many of which sprang up this year, the CMA’s general counsel, Sarah Cardell, wrote, “PCR test providers should be in no doubt that they need to get on the right side of the law. If they don’t, they risk enforcement action.
“This warning goes hand in hand with action taken by the government this week and is the latest step in our work to tackle rip-off prices and bad service. We continue to work closely with [the Department of Health and Social Care] in reviewing this market and will be providing further advice to DHSC on action that can be taken.”
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas